Sodium-glucose cotransporter-2 inhibitors have shown modest HbA1c reductions with small but clinically meaningful weight loss in T1DM; however, they are associated with an increased risk of diabetic ketoacidosis. This evidence concerns the gene SLC5A2 and type 1 diabetes mellitus.